{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T00:54:09Z","timestamp":1794012849143,"version":"4.8.0"},"reference-count":75,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,9,25]],"date-time":"2023-09-25T00:00:00Z","timestamp":1695600000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Psoriasis is a chronic inflammatory skin disease characterized by hyperplasia of keratinocytes and immune cell infiltration. The IL-17-producing T cells play a key role in psoriasis pathogenesis, while regulatory T (Treg) cells are diminished during psoriatic inflammation. Current psoriasis treatments largely focus on IL-17 and IL-23, however, few studies have explored therapeutic drugs targeting an increase of Treg cells to control immune homeostasis. In this study, we investigated the effects of a cytotoxic T lymphocyte antigen-4 (CTLA-4) signaling peptide (dNP2-ctCTLA-4) in Th17, Tc17, \u03b3\u03b4 T cells, Treg cells <jats:italic>in vitro<\/jats:italic> and a mouse model of psoriasis. Treatment with dNP2-ctCTLA-4 peptide showed a significant reduction of psoriatic skin inflammation with increased Treg cell proportion and reduced IL-17 production by T cells, indicating a potential role in modulating psoriatic skin disease. We compared dNP2-ctCTLA-4 with CTLA-4-Ig and found that only dNP2-ctCTLA-4 ameliorated the psoriasis progression, with increased Treg cells and inhibited IL-17 production from \u03b3\u03b4 T cells. <jats:italic>In vitro<\/jats:italic> experiments using a T cell-antigen presenting cell co-culture system demonstrated the distinct mechanisms of dNP2-ctCTLA-4 compared to CTLA-4-Ig in the induction of Treg cells. These findings highlight the therapeutic potential of dNP2-ctCTLA-4 peptide in psoriasis by augmenting Treg\/Teff ratio, offering a new approach to modulating the disease.<\/jats:p>","DOI":"10.3389\/fimmu.2023.1233514","type":"journal-article","created":{"date-parts":[[2023,9,26]],"date-time":"2023-09-26T05:17:04Z","timestamp":1695705424000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":25,"title":["Alleviating psoriatic skin inflammation through augmentation of Treg cells via CTLA-4 signaling peptide"],"prefix":"10.3389","volume":"14","author":[{"given":"Woo-Sung","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyung-Ho","family":"Nam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jong Hoon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Won-Ju","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeong Eun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eui-Cheol","family":"Shin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gil-Ran","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Je-Min","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,9,25]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1056\/NEJMra0804595","article-title":"Psoriasis","volume":"361","author":"Nestle","year":"2009","journal-title":"N Engl J Med"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)32549-6","article-title":"Psoriasis","volume":"397","author":"Griffiths","year":"2021","journal-title":"Lancet"},{"key":"B3","doi-asserted-by":"publisher","first-page":"16082","DOI":"10.1038\/nrdp.2016.82","article-title":"Psoriasis","volume":"2","author":"Greb","year":"2016","journal-title":"Nat Rev Dis Primers."},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-immunol-032713-120225","article-title":"Immunology of psoriasis","volume":"32","author":"Lowes","year":"2014","journal-title":"Annu Rev Immunol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)61909-7","article-title":"Psoriasis","volume":"386","author":"Boehncke","year":"2015","journal-title":"Lancet"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2009.59","article-title":"The IL-23\/Th17 axis in the immunopathogenesis of psoriasis","volume":"129","author":"Di Cesare","year":"2009","journal-title":"J Invest Dermatol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1146\/annurev-immunol-082919-093554","article-title":"Innate lymphocyte mechanisms in skin diseases","volume":"38","author":"Chen","year":"2020","journal-title":"Annu Rev Immunol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00242","article-title":"Innate lymphocytes in psoriasis","volume":"11","author":"Polese","year":"2020","journal-title":"Front Immunol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1100804","article-title":"Identification of a novel proinflammatory human skin-homing Vgamma9Vdelta2 T cell subset with a potential role in psoriasis","volume":"187","author":"Laggner","year":"2011","journal-title":"J Immunol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1172\/JCI61862","article-title":"Rorgammat+ innate lymphocytes and gammadelta T cells initiate psoriasiform plaque formation in mice","volume":"122","author":"Pantelyushin","year":"2012","journal-title":"J Clin Invest."},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1038\/nri2800","article-title":"Innate IL-17-producing cells: the sentinels of the immune system","volume":"10","author":"Cua","year":"2010","journal-title":"Nat Rev Immunol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2020.11.023","article-title":"Dissecting the complexity of gammadelta T-cell subsets in skin homeostasis, inflammation, and Malignancy","volume":"147","author":"Castillo-Gonzalez","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.649408","article-title":"Cutaneous and systemic psoriasis: classifications and classification for the distinction","volume":"8","author":"Yan","year":"2021","journal-title":"Front Med (Lausanne)."},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.4006","article-title":"Pathophysiology, clinical presentation, and treatment of psoriasis: A review","volume":"323","author":"Armstrong","year":"2020","journal-title":"JAMA"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.7326\/AITC201804030","article-title":"Psoriasis","volume":"168","author":"Lebwohl","year":"2018","journal-title":"Ann Intern Med"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1038\/nrd2996","article-title":"Psoriasis market","volume":"8","author":"Melnikova","year":"2009","journal-title":"Nat Rev Drug Discovery"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00184-7","article-title":"Therapeutics targeting the IL-23 and IL-17 pathway in psoriasis","volume":"397","author":"Ghoreschi","year":"2021","journal-title":"Lancet"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.4110\/in.2022.22.e7","article-title":"Immunopathology and immunotherapy of inflammatory skin diseases","volume":"22","author":"Song","year":"2022","journal-title":"Immune Netw"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD011535.pub5","article-title":"Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis","volume":"5","author":"Sbidian","year":"2022","journal-title":"Cochrane Database Syst Rev"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-019-0175-7","article-title":"Regulatory T cells in cancer immunosuppression - implications for anticancer therapy","volume":"16","author":"Togashi","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2008.05.009","article-title":"Regulatory T cells and immune tolerance","volume":"133","author":"Sakaguchi","year":"2008","journal-title":"Cell"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1038\/nri2343","article-title":"How regulatory T cells work","volume":"8","author":"Vignali","year":"2008","journal-title":"Nat Rev Immunol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.03100","article-title":"Treg heterogeneity, function, and homeostasis","volume":"10","author":"Shevyrev","year":"2019","journal-title":"Front Immunol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.immunol.25.022106.141623","article-title":"Regulatory T cells: mechanisms of differentiation and function","volume":"30","author":"Josefowicz","year":"2012","journal-title":"Annu Rev Immunol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.0803721","article-title":"IL-6 signaling in psoriasis prevents immune suppression by regulatory T cells","volume":"183","author":"Goodman","year":"2009","journal-title":"J Immunol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.174.1.164","article-title":"Dysfunctional blood and target tissue CD4+CD25high regulatory T cells in psoriasis: mechanism underlying unrestrained pathogenic effector T cell proliferation","volume":"174","author":"Sugiyama","year":"2005","journal-title":"J Immunol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.jdermsci.2015.11.007","article-title":"Impaired function of regulatory T cells in patients with psoriasis is mediated by phosphorylation of STAT3","author":"Yang","year":"2016","journal-title":"J Dermatol Sci"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1038\/nri2889","article-title":"Mechanisms of impaired regulation by CD4(+)CD25(+)FOXP3(+) regulatory T cells in human autoimmune diseases","volume":"10","author":"Buckner","year":"2010","journal-title":"Nat Rev Immunol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-018-0120-4","article-title":"Regulatory T cells in autoimmune disease","volume":"19","author":"Dominguez-Villar","year":"2018","journal-title":"Nat Immunol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2011.139","article-title":"Foxp3+ regulatory T cells of psoriasis patients easily differentiate into IL-17A-producing cells and are found in lesional skin","volume":"131","author":"Bovenschen","year":"2011","journal-title":"J Invest Dermatol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2011.200","article-title":"The dark side of regulatory T cells in psoriasis","volume":"131","author":"Soler","year":"2011","journal-title":"J Invest Dermatol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.4110\/in.2017.17.5.276","article-title":"IL-17A-producing foxp3(+) regulatory T cells and human diseases","volume":"17","author":"Jung","year":"2017","journal-title":"Immune Netw"},{"key":"B33","doi-asserted-by":"publisher","first-page":"3564","DOI":"10.1016\/j.celrep.2018.12.012","article-title":"Regulatory T cells restrain pathogenic T helper cells during skin inflammation","volume":"25","author":"Hartwig","year":"201","journal-title":"Cell Rep"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20172094","article-title":"Foxp3(+) T reg cells control psoriasiform inflammation by restraining an IFN-I-driven CD8(+) T cell response","volume":"215","author":"Stockenhuber","year":"2018","journal-title":"J Exp Med"},{"key":"B35","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.jdermsci.2020.04.008","article-title":"Regulatory T cells suppress skin inflammation in the imiquimod-induced psoriasis-like mouse model","volume":"98","author":"Choi","year":"2020","journal-title":"J Dermatol Sci"},{"key":"B36","doi-asserted-by":"publisher","first-page":"8244","DOI":"10.1038\/ncomms9244","article-title":"dNP2 is a blood-brain barrier-permeable peptide enabling ctCTLA-4 protein delivery to ameliorate experimental autoimmune encephalomyelitis","volume":"6","author":"Lim","year":"2015","journal-title":"Nat Commun"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmed.2022.03.010","article-title":"Unleashing cell-penetrating peptide applications for immunotherapy","volume":"28","author":"Koo","year":"2022","journal-title":"Trends Mol Med"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202004973","article-title":"In vivo induction of regulatory T cells via CTLA-4 signaling peptide to control autoimmune encephalomyelitis and prevent disease relapse","volume":"8","author":"Kim","year":"2021","journal-title":"Adv Sci (Weinh)."},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2018.08.049","article-title":"Regulation of human T cell responses by dNP2-ctCTLA-4 inhibits human skin and microvessel graft rejection","volume":"183","author":"Lim","year":"2018","journal-title":"Biomaterials"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1038\/emm.2017.107","article-title":"dNP2-ctCTLA-4 inhibits German cockroach extract-induced allergic airway inflammation and hyper-responsiveness via inhibition of Th2 responses","volume":"49","author":"Lim","year":"2017","journal-title":"Exp Mol Med"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2017.04.007","article-title":"Protein tyrosine phosphatase conjugated with a novel transdermal delivery peptide, astrotactin 1-derived peptide recombinant protein tyrosine phosphatase (AP-rPTP), alleviates both atopic dermatitis-like and psoriasis-like dermatitis","volume":"141","author":"Kim","year":"2018","journal-title":"J Allergy Clin Immunol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.0802999","article-title":"Imiquimod-induced psoriasis-like skin inflammation in mice is mediated via the IL-23\/IL-17 axis","volume":"182","author":"van der Fits","year":"2009","journal-title":"J Immunol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2006.03.001","article-title":"CTLA4Ig: bridging the basic immunology with clinical application","volume":"24","author":"Bluestone","year":"2006","journal-title":"Immunity"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1038\/ncprheum0345","article-title":"Drug Insight: abatacept for the treatment of rheumatoid arthritis","volume":"2","author":"Ruderman","year":"2006","journal-title":"Nat Clin Pract Rheumatol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.immunol.19.1.565","article-title":"CTLA-4-mediated inhibition in regulation of T cell responses: mechanisms and manipulation in tumor immunotherapy","volume":"19","author":"Chambers","year":"2001","journal-title":"Annu Rev Immunol"},{"key":"B46","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1038\/s41577-018-0084-5","article-title":"The immunological anatomy of the skin","volume":"19","author":"Kabashima","year":"2019","journal-title":"Nat Rev Immunol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-018-0256-2","article-title":"The epithelial immune microenvironment (EIME) in atopic dermatitis and psoriasis","volume":"19","author":"Dainichi","year":"2018","journal-title":"Nat Immunol"},{"key":"B48","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1038\/nri3646","article-title":"Mechanisms regulating skin immunity and inflammation","volume":"14","author":"Pasparakis","year":"2014","journal-title":"Nat Rev Immunol"},{"key":"B49","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1016\/j.immuni.2011.08.001","article-title":"Pivotal role of dermal IL-17-producing gammadelta T cells in skin inflammation","volume":"35","author":"Cai","year":"2011","journal-title":"Immunity"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1002\/eji.201545883","article-title":"Dermal IL-17-producing gammadelta T cells establish long-lived memory in the skin","volume":"45","author":"Hartwig","year":"2015","journal-title":"Eur J Immunol"},{"key":"B51","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.1016\/j.jaci.2015.11.021","article-title":"Programmed cell death ligand 1 alleviates psoriatic inflammation by suppressing IL-17A production from programmed cell death 1-high T cells","volume":"137","author":"Kim","year":"2016","journal-title":"J Allergy Clin Immunol"},{"key":"B52","doi-asserted-by":"publisher","first-page":"3034","DOI":"10.1016\/j.celrep.2019.05.019","article-title":"Differential Roles of the mTOR-STAT3 Signaling in Dermal gammadelta T Cell Effector Function in Skin Inflammation","volume":"27","author":"Cai","year":"2019","journal-title":"Cell Rep"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2009.08.001","article-title":"Interleukin-1 and IL-23 induce innate IL-17 production from gammadelta T cells, amplifying Th17 responses and autoimmunity","volume":"31","author":"Sutton","year":"2009","journal-title":"Immunity"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1700826","article-title":"IL-17-Secreting gammadelta T Cells Are Completely Dependent upon CCR6 for Homing to Inflamed Skin","volume":"199","author":"Campbell","year":"2017","journal-title":"J Immunol"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2012.260","article-title":"CCR6 is required for epidermal trafficking of gammadelta-T cells in an IL-23-induced model of psoriasiform dermatitis","volume":"133","author":"Mabuchi","year":"2013","journal-title":"J Invest Dermatol"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1172\/jci37378","article-title":"CCR6 is required for IL-23-induced psoriasis-like inflammation in mice","volume":"119","author":"Hedrick","year":"2009","journal-title":"J Clin Invest."},{"key":"B57","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1016\/j.immuni.2010.10.014","article-title":"T regulatory cells maintain intestinal homeostasis by suppressing gammadelta T cells","volume":"33","author":"Park","year":"2010","journal-title":"Immunity"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1002\/eji.201141814","article-title":"CD4+ Foxp3+ regulatory T cells suppress gammadelta T-cell effector functions in a model of T-cell-induced mucosal inflammation","volume":"41","author":"Yurchenko","year":"2011","journal-title":"Eur J Immunol"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-02-139899","article-title":"CD4+ CD25+ Treg cells inhibit human memory gammadelta T cells to produce IFN-gamma in response to M tuberculosis antigen ESAT-6","volume":"111","author":"Li","year":"2008","journal-title":"Blood"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0155689","article-title":"Cell type preference of a novel human derived cell-permeable peptide dNP2 and TAT in murine splenic immune cells","volume":"11","author":"Lim","year":"2016","journal-title":"PloS One"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.14348\/molcells.2022.2056","article-title":"Current understanding of cytotoxic T lymphocyte antigen-4 (CTLA-4) signaling in T-cell biology and disease therapy","volume":"45","author":"Kim","year":"2022","journal-title":"Mol Cells"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0805198105","article-title":"Transduction of the cytoplasmic domain of CTLA-4 inhibits TcR-specific activation signals and prevents collagen-induced arthritis","volume":"105","author":"Choi","year":"2008","journal-title":"Proc Natl Acad Sci U S A."},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1038\/nm1385","article-title":"Intranasal delivery of the cytoplasmic domain of CTLA-4 using a novel protein transduction domain prevents allergic inflammation","volume":"12","author":"Choi","year":"2006","journal-title":"Nat Med"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1038\/35105024","article-title":"T-cell regulation by CD28 and CTLA-4","volume":"1","author":"Alegre","year":"2001","journal-title":"Nat Rev Immunol"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1801425","article-title":"Abatacept targets T follicular helper and regulatory T cells, disrupting molecular pathways that regulate their proliferation and maintenance","volume":"202","author":"Glatigny","year":"2019","journal-title":"J Immunol"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2011.03929.x","article-title":"Deleterious effect of CTLA4-Ig on a Treg-dependent transplant model","volume":"12","author":"Riella","year":"2012","journal-title":"Am J Transplant."},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.12712","article-title":"Renal transplantation using belatacept without maintenance steroids or calcineurin inhibitors","volume":"14","author":"Kirk","year":"2014","journal-title":"Am J Transplant."},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-210724","article-title":"Efficacy and safety of abatacept, a T-cell modulator, in a randomised, double-blind, placebo-controlled, phase III study in psoriatic arthritis","volume":"76","author":"Mease","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2021.3492","article-title":"Effect of costimulatory blockade with abatacept after ustekinumab withdrawal in patients with moderate to severe plaque psoriasis: the PAUSE randomized clinical trial","volume":"157","author":"Harris","year":"2021","journal-title":"JAMA Dermatol"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1038\/ni.2866","article-title":"Protein kinase C-eta controls CTLA-4-mediated regulatory T cell function","volume":"15","author":"Kong","year":"2014","journal-title":"Nat Immunol"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2013.12.036","article-title":"Interleukin 17A: toward a new understanding of psoriasis pathogenesis","volume":"71","author":"Lynde","year":"2014","journal-title":"J Am Acad Dermatol"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.15921","article-title":"Ixekizumab sustains high level of efficacy and favourable safety profile over 4 years in patients with moderate psoriasis: results from UNCOVER-3 study","volume":"34","author":"Lebwohl","year":"2020","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2016.1177158","article-title":"Review of maintenance of response to psoriasis treatments","volume":"27","author":"Bartos","year":"2016","journal-title":"J Dermatolog Treat"},{"key":"B74","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.jid.2020.04.031","article-title":"Induction of regulatory T cells and correction of cytokine disbalance by short-chain fatty acids: implications for psoriasis therapy","volume":"141","author":"Schwarz","year":"2021","journal-title":"J Invest Dermatol"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdermsci.2018.08.007","article-title":"The vitamin D(3) analog, maxacalcitol, reduces psoriasiform skin inflammation by inducing regulatory T cells and downregulating IL-23 and IL-17 production","volume":"92","author":"Hau","year":"2018","journal-title":"J Dermatol Sci"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1233514\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,26]],"date-time":"2023-09-26T05:17:07Z","timestamp":1695705427000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1233514\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,25]]},"references-count":75,"alternative-id":["10.3389\/fimmu.2023.1233514"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2023.1233514","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,25]]},"article-number":"1233514"}}